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Abstract 
Oncolytic viruses (OV) are engineered to replicate only within tumor cells, spreading 
within and destroying malignant gliomas without harming non-neoplastic cells.  While clinical 
trials have confirmed its safety, the evidence for efficacy of OV therapy remains elusive.  To 
enhance OV efficacy, a correlation linking the level of intratumoral OV over time and patient 
outcome/response is necessary.  However, such a correlation is currently infeasible due to the 
lack of available biomarkers that faithfully reflect OV activity in tumors. 
An initial transcript profiling of human glioma cell lines in vitro treated with OV revealed 
significant and consistent cysteine-rich 61 protein (CYR61) induction that mirrored OV 
presence.  CYR61 is a secreted heparin-binding protein that is over-expressed in a majority of 
tumors, including glioma, and is a potent angiogenic factor.  Thus, we hypothesized that CYR61 
mRNA and protein expression will be up-regulated upon OV infection in most glioma cell lines 
both in vitro and in vivo, thereby indicating its use as a reliable biomarker to evaluate the 
efficacy of ongoing OV infection and replication in tumors.    
CYR61 mRNA induction by OV infection in vitro was evaluated in 4 human glioma cell 
lines and 6 patient derived human tumor specimens using Quantitative Real Time PCR (QRT-
PCR), and was confirmed in 9 out of 10 gliomas tested.  We further confirmed the induction of 
CYR61 protein by western blot analysis of infected U343, U87, and U87ΔEGFR cells.   
To verify the induction of CYR61 in vivo, we implanted intracerebral tumors (human 
U87ΔEGFR cells) in athymic nude mice and treated the tumors with OV or PBS.  The harvested 
tumor tissue samples were analyzed for CYR61 protein expression.  Finally, we checked the 
induction of CYR61 protein in tumors derived from human gliomas and implanted in athymic 
nude mice by immunofluorescent staining and confocal fluorescent microscopy.   
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 The significant correlation between the levels of induced CYR61 and OV in tumor tissue 
indicates the potential usefulness of CYR61 as a biomarker for viral oncolysis in the tumor 
microenvironment.  Our results indicate the importance of incorporating such measurements in 
future clinical trials using OV therapy to aid in the development of better therapeutic strategies. 
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Introduction 
Brain Tumors: A Devastating Disease for Patients and their Families 
 The American Cancer Society estimates that 20,500 new cases of cancers of the brain and 
central nervous system (CNS) and 12,740 deaths from such malignancies will be reported in the 
United States in 2007.  The World Health Organization (WHO) classifies brain tumors into 
different grades from low (Grade I) to high (Grade IV) (Figure 1).  Pilocytic astrocytomas 
(Grade 1) are non-infiltrative, biologically benign tumors that are usually curable upon resection 
1.  The lowest grade of infiltrative astrocytoma (Grade II) is characterized by increased 
cellularity resulting from the percolation of neoplastic cells through the normal brain 
parenchyma.  These tumors are most common in the cerebral hemispheres and are further 
typified by enlarged, hyperchromatic nuclei and irregular nuclear contours.  Anaplastic 
astrocytomas (Grade III) represent a transition phase between Grades II and IV.  These 
astrocytomas are characterized by the presence of nuclear pleomorphism, atypia, increased 
cellularity, and increased rate of proliferation.  Glioblastoma multiforme (GBM), the highest 
grade of infiltrating astrocytoma, is described by the development of microvascular hyperplasia 
and/or necrosis surrounded by areas of high cellularity called pseudopalisades.  Microvascular 
hyperplasia results from aberrant proliferation of endothelial cells, which often manifest as tufted 
microaggregates emerging from parent blood vessels.  These aggregates are shaped like renal 
glomeruli and are therefore called “glomeruloid bodies” 2. 
 Current treatments for patients include surgical resection, radiation, and/or chemotherapy.  
Despite aggressive tumor resections followed by adjuvant therapy, the mean survival of patients 
diagnosed with GBM is about 14 months 2.  Decades of research have uncovered various 
molecular genetic alterations in these tumors and have led to the design of several targeted 
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Figure 1: Schematic of World Health Organization’s (WHO) Grades 
of Infiltrative Astrocytoma. 
Schematic diagram of the histopathological progression of WHO infiltrative astrocytoma, 
grades II to IV.   
 
Grade II brain tumors consist of individual tumor cells percolating through the CNS 
parenchyma.  The vascular architecture and blood vessel density is similar to that of normal 
CNS tissue.  Grade III infiltrative astrocytoma is characterized by increased cellular density, 
atypical morphology, and mitotic figures in anaplastic astrocytoma.  They are accompanied by 
increasing vessel density.  Glioblastoma multiforme (Grade IV malignant astrocytomas) are 
depicted with representative microvascular hyperplasia, glomeruloid vascularization (open 
arrow), and necrosis with pseudopalisading (black arrows).  (Adapted from Brat, et al., Adv Anat 
Pathol, 2002 2). 
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therapeutics.  However, despite intensive therapeutic interventions, these tumors are rarely 
curable 3.  The dismal nature of this disease underscores the need for radical treatment strategies.   
Viral Oncolytic Therapy (VOLT): An Extreme Treatment for an Extreme Disease 
Oncolytic virus (OV) therapy is a radical biological strategy being tested in several 
clinical trials in patients with malignant astrocytomas.  OVs are viruses that can infect and 
replicate selectively within tumor cells, but not in normal non-neoplastic cells (Figure 2) 4,5.  
Subsequent replicative cycles of the propagated virus particles enable the destruction of the 
tumor with minimal damage to non-cancerous tissue.  Tumor-specific OVs are created via 
genetic manipulations of naturally occurring viruses, resulting in attenuated viruses that can 
replicate only in permissive cancer cells and normal cells.  Some naturally occurring viruses also 
have a natural propensity to replicate in a tumor-specific manner and are exploited for therapy 6. 
Oncolytic DNA viruses, such as herpes simplex virus- type 1 (HSV-1) and adenoviruses, 
are being tested in clinical trials and have revealed the relative safety of such a treatment 
modality 7.  A recently published report of a dose-escalating, multi-institutional trial using 
ONYX-015 (an attenuated adenovirus mutated for its E1B gene) revealed that when it was 
injected into glioma cavities, it was tolerated at doses as high as 1010 plaque forming units 
(p.f.u.) 8.  HSV-1–based OVs are particularly exciting because 9,10:  
1. HSV has the natural ability to infect a wide range of tissues, thereby making it 
applicable for treating a wide variety of tumors. 
2. The inherent cytolytic nature of the virus combined with its ability to amplify 
to a large burst size gives it an oncolytic advantage.   
3. HSV-1 has a large (152 kb) genome that is very well characterized.  This 
provides ample opportunity for genetic manipulation to impart tumor selective  
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Mechanism of tumor specific destruction by OV therapy.   
 
The principle of oncolysis by a conditionally replication-competent virus is demonstrated by 
tumor-specific replication of the virus.  The left panel shows the initial infection of cancer cells 
(orange filled circles) and normal cells (blue filled circles) by infectious viral particles (purple 
dots).  The tumor-specific replication ability of the virus results in virus replication only within 
the tumor cells (gray), but not in normal cells (blue).  Note the destruction of tumor cells by the 
replicating virus, leaving adjacent normal tissue intact.  (Adapted from Aguilar-Cordova E, 
Nature Biotech, 2003 5). 
Figure 2: Oncolytic Virus (OV) Selective Infection and Destruction 
of Tumor Cells. 
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replication potential to the virus.  Additionally, many of the non-essential viral 
genes (up to 30kb) can be replaced by therapeutic genes.  
4. The inherent ability of HSV-1 virus to remain as an episome without inserting 
into the genome avoids the possibility of further insertional mutations in the 
already unstable cancer genome.   
5. Finally, several anti-herpetic drugs commonly used in clinics can keep viral 
replication in check, if needed.   
HSV-1–Based Oncolytic Viruses: The Clinical Story 
The well-characterized genome of HSV-1 permits several strategies for manipulating 
genes to enable the tumor-selective replication of the virus.  ICP6 and γ34.5 are two genetic loci 
that are frequently disrupted or otherwise altered to obtain conditionally replication-competent 
OVs (Figure 3a).  The ICP6 gene, found at the UL39 locus, is known to code for ribonucleotide 
reductase (RR).  ICP6/RR is necessary for viral replication in normal non-dividing cells because 
it is essential for the nucleotide synthesis required in DNA replication 11-14.  The absence of RR 
renders the virus unable to replicate in non-dividing cells, such as neurons, thus conferring tumor 
specificity to the virus.  The γ34.5 gene is encoded within repeat sequences in the viral genome 
(TRL, and IRL), and hence occurs twice in the wild-type HSV-1 genome.  These regions are 
primarily responsible for viral neurovirulence because the gene prevents the disruption of protein 
synthesis that normally occurs in an infected cell’s response to viral replication.  Removing both 
copies of γ34.5 reduces the neurovirulence of the virus by eliminating its ability to replicate in 
terminally differentiated cells 3. 
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Figure 3: HSV-1-Derived OVs Evaluated in Clinical Trials.   
Schematic of wild type HSV-1 and two HSV derivatives tested in clinical studies: HSV 1716 
and G207. 
 
a:  HSV-1 genome structure showing the UL (Unique long sequences) and US (Unique small 
sequences).  Enlargements of the UL region depict the γ34.5 and ICP6 domains. 
 
b:  HSV 1716 is an HSV-1-derived OV, in which both copies of γ34.5 have been deleted, but the 
ICP6/RR gene is retained.  This mutation confers tumor specificity to the virus by rendering the 
virus unable to replicate in normal cells. 
 
c:  G207 is second-generation HSV-1 derivative wherein both copies of γ34.5 have been deleted, 
along with the ICP6/RR region.  These deletions result in significantly decreased neurovirulence 
and increased tumor specificity in OV therapy.   
a. HSV-1 TRL TRS 
UL US IRL IRS
ICP6/RR γ34.5γ34.5 
HSV 1716 b. ICP6/RR 
Δ γ34.5 Δ γ34.5
X X 
G207 c. X 
Δ γ34.5 Δ γ34.5
X X 
Δ ICP6/RR 
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 1716 is an oncolytic HSV from which both copies of γ34.5 have been deleted, but it 
retains a functional ICP6/RR gene (Figure 3b).  In rodent models, this virus effectively 
destroyed rapidly dividing tumor cells without infecting surrounding brain tissue.  In Glasgow, 
Scotland, three clinical trials have confirmed the safety of HSV 1716 as an OV.  In the first trial, 
no adverse side effects were observed in patients suffering from recurrent malignant glioma who 
were treated with intratumoral inoculations of HSV 1716 at doses as high as 105 p.f.u.  In the 
second trial, patients received 105 p.f.u. of HSV 1716 administered intratumorally.  After four to 
nine days, resected tumors were found to have actively replicating HSV in tumor sites adjacent 
and distal to the site of inoculation.  Again, no adverse symptoms were observed.  The third 
study targeted residual disease by inoculating the tumor cavity following surgical resection.  No 
signs of toxicity were observed, and three of the twelve patients survived long term (15 to 22 
months) after this treatment.  These clinical trials validated claims of the safety of OV therapy 
and provided evidence of the treatment’s efficacy in a subset of patients 3. 
 G207 is a second-generation HSV-1 derived OV whose safety has been substantiated in 
various rodent models and preclinical toxicology studies.  The deletion of ICP6/RR and both 
copies of γ34.5 enable its tumor selectivity (Figure 3c).  Both in vitro and in vivo, infection with 
G207 killed glioma cells without signs of neurovirulence.  Furthermore, preclinical studies in a 
rodent model displayed the efficacy of G207 in treating various tumor types.  From these studies, 
a Phase 1 clinical trial using oncolytic HSV-1 was developed, in which the safety of OV therapy 
was confirmed 3.   
Reovirus and a strain of Newcastle disease virus are other OVs undergoing clinical trials.  
Various strategies to enhance tumor targeting of HSV, adenoviruses, and measles virus have 
yielded encouraging results in preclinical studies of rodent models of cancer  15-18.  Viruses 
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employed as vehicles for gene transfer to cancer cells have also shown therapeutic efficacy in 
mice 19-22.  Despite significant advances, however, there remains a strong need for continued 
investigation into novel therapeutic agents for the treatment of brain cancer.   
Possible limitations of VOLT in clinical trials 
Although the safety of OV therapy has been confirmed in clinical trials, its efficacy 
remains unproven 3,4.  A thorough examination of possible reasons for the observed low efficacy 
is crucial to optimize benefit from this very promising treatment strategy.  Inefficient viral 
spread, the highly attenuated nature of first-generation OVs, rapid viral clearance, technology 
limitations in viral production, and the lack of prognostic indicators for patient selection are 
thought to be some of the limitations to the success of VOLT.   
The first generation of viruses that underwent clinical trials were designed to be highly 
attenuated due to overriding safety concerns.  This attenuation may have been responsible for the 
decreased efficacy of infection of cancerous cells that was observed in the trials.  The restricted 
expression of viral receptors on most cancer cells may also contribute to the decreased ability of 
virus to infect cancer cells.  Both of these hindrances require the engineering of a second 
generation of genetically modified OVs that are more potent, but maintain current levels of 
safety 4,11. 
Brain tumors, like other solid tumors, are composed of neoplastic cells as well as normal 
stromal cells embedded in an extracellular matrix (ECM) composed of secreted proteins, 
proteases, and growth factors.  The complex ECM of a solid tumor plays a very significant role 
in limiting the spread of large therapeutic molecules, such as a virus, to distal regions of the 
tumor.  Modulation of the ECM has been shown to enhance viral spread and thereby increase 
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OV efficacy 23,24.  Thus, efforts to understand and modify the tumor microenvironment are 
essential to enhance viral efficacy 4. 
Limitations in current technology may also hinder therapeutic efficacy because the 
viruses may not be produced at high enough titers to be effective.  However, this idea contradicts 
the underlying principle of virus therapy, wherein a single viral particle should be able to infect, 
replicate, and destroy the entire mass of tumor cells.  Though this theory holds true in vitro, after 
initial OV inoculation in vivo, viral titers in tumors have been observed to decline 4,25.  
The decrease in viral titers in vivo may result from the rapid neutralization, degradation, 
and clearance of viral particles that result from the host’s immune response 4.  Upon infection 
with virus, the host’s innate immune response is activated, which then stimulates viral clearance 
from cells and thereby limits further OV therapy 26-28.  This theory is bolstered by recent 
observations that transient immune suppression using cyclophosphamide (CPA) enhanced the 
therapeutic efficacy of the administered OV by reducing viral clearance by the host’s innate 
immune responses, thus allowing better oncolysis of tumor tissue (Figure 4) 28,29.  On the other 
hand, OV-mediated lysis of cancer cells is also thought to be responsible for activating a 
systemic adaptive anti-tumor immune response 30-32.  The significance of these paradoxical 
effects of the host immune responses on the OV therapy is not very clear.   
Despite anecdotal reports of patients’ with brain tumors responding to OV therapy, its 
efficacy has not been proven.  Due to limitations in current technology it is not possible to 
correlate individual patient responses with effective OV infection, replication, and propagation in 
tumors 6.  OV efficacy is currently measured by assessing the presence of viral particles and/or 
lysed tumor cells in patient serum.  However, neither of these markers accurately represents OV 
activity and may actually reflect either viral clearance or tumor destruction by anti-tumor 
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CPA pretreatment suppresses host immune responses, thereby inhibiting rapid viral 
clearance and allowing increased viral replication.  
 
Immunohistochemistry for HSV capsid protein on brain sections derived from tumor bearing 
rats with tumors treated with CPA and/or HSV-1-derived OV, as indicated.  Panel a depicts a 
representative tumor section from animals treated with oncolytic virus hrR3 alone.  In panel b, a 
typical section is shown from animals treated with hrR3 and CPA on the same day.  Panel c 
depicts a representative section of tumors harvested from animals that were pretreated with CPA 
2 days prior to hrR3 treatment.  In each panel, the brown precipitates are indicative of HSV 
capsid antigen expression.  Note the significant increase in HSV presence in tumors from 
animals pretreated with CPA.  This increase indicates CPA inhibition of viral clearance, which 
allows increased viral replication and infection.  The scale bar represents 100 μm.  (Adapted 
from Wakimoto, et al.  Gene Ther, 2004 29) 
Figure 4: Cyclophosphamide (CPA) Pretreatment Suppresses Host 
Immune Responses Responsible for Rapid Viral Clearance.   
 
 17
immune responses.  This underscores the need for development of a biomarker that (1) can 
accurately reflect OV activity in patient tumors, and (2) can be used to correlate its presence with 
patient response in clinical trials.  
We have been elucidating changes in tumor microenvironment in response to OV therapy 
and have identified the induction of cysteine-rich protein 61 (CYR61) in glioma cells upon 
infection with oncolytic HSV.   
Cysteine-rich Protein 61 (CYR61): A Potential Biomarker for OV Activity 
CYR61 is a ≈ 40kDa secreted heparin-binding protein encoded by a growth factor-
inducible immediate-early gene.  CYR61 is a member of the Cysteine-rich 61/Connective tissue 
growth factor/Nephroblastoma overexpressed (CCN) family of growth factors 1,33-35.  The protein 
sequence predicts it to have several conserved domains (SMART domain analysis: 
http://smart.embl-heidelberg.de/smart/show_motifs.pl, 5/4/2007): IGFBP-domain, von 
Willebrand factor-domain, thrombospondin-domain, and a C-terminal cysteine knot (Figure 5). 
These conserved domains, when compared to proteins with homologous amino acid 
sequences, reveal some potential functions of the CYR61 protein.  For example, insulin growth 
factor-binding proteins (IGFBP) prolong the half-life of insulin-like growth factors (IGF) and 
seem to alter the interactions between IGFs and their cell surface receptors.  In cell culture, 
IGFBPs have been observed to either inhibit or stimulate the growth-promoting effects of IGFs.   
The von Willebrand factor (VWF) type C repeat is found in various plasma proteins: 
complement factors B, C2, CR3 and CR4; the integrins (I-domains); collagen types VI, VII, XII 
and XIV; and other extracellular proteins.  Most VWF-containing proteins are extracellular and 
involved in multiprotein complexes.  This domain is often found in multidomain/multifunctional 
proteins involved in homeostasis.  Proteins containing VWF domains also participate in cell 
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Prediction of CYR61’s domain structure by comparison to homologous domains. 
 
IB:  Insulin growth factor-binding protein (IGFBP) domain is found in IGFBP.  The IGFBP are 
characterized by high affinity binding to insulin-like growth factors (IGF).  Position in CYR61: 
amino acids 24 to 93; E-value = 1.16e-24. 
 
VWC:  von Willebrand factor type C domain is common in extracellular proteins that are 
involved in multi-protein complexes.  Position in CYR61: amino acids 100 to 163; E-value = 
3.28e-23. 
 
TSP-1:  Thrombospondin type 1 repeats bind and activate TGF-beta.  Position in CYR61: amino 
acids 231 to 273; E-value = 5.43e-06. 
 
CT:  C-terminal cystine knot-like domain (CTCK) is a non-globular domain that is predicted to 
form homo- and heterodimers.  Position in CYR61: amino acids 291 to 360; E-value = 6.88e-23. 
 
(Adapted from SMART domain analysis: http://smart.embl-heidelberg.de/smart/show_motifs.pl, 
5/4/2007) 
Figure 5: Predicted Domain Structure of Cyr61. 
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adhesion, migration, homing, pattern formation, signal transduction, and interactions with 
ligands.   
The thrombospondin type 1 (TSP-1) repeat has been identified in thrombospondin 
protein; complement pathway proteins (properdin, C6, C7, C8A, C8B, C9); and extracellular 
matrix proteins (mindin, F-spondin, SCO-spondin, circumsporozoite surface protein 2, and 
TRAP proteins of Plasmodium).  The TSP-1 domain is associated with cell-to-cell interaction, 
apoptosis, and inhibition of angiogenesis.   
Despite a lack of sequence homology, the C-terminal cystine knot-like (CTCK) region is 
characterized by a distinctive arrangement of six cysteines that form a “cystine-knot” and is 
shared by structurally related growth factors from four different superfamilies.  As a result of 
their distinctive shape, these proteins are active as either homo- or heterodimers (SMART 
domain analysis: http://smart.embl-heidelberg.de/smart/show _motifs.pl).     
CYR61 is expressed in a variety of cells, including those of the vasculature and the 
muscle, bone and nervous systems.  It is also expressed highly during development and in 
pathological states in adulthood 36.  Because of its ability to bind to heparin sulfate 
proteoglycans, CYR61 is associated with the ECM and cell surface, and thus is usually not 
detected in the culture medium 34,37.  Consistent with its localization in the ECM, CYR61 
functions as a cellular adhesion molecule that is key in communicating changes in the cellular 
environment to the cell  37,38.  It is known to promote cell proliferation, adhesion, migration, and 
differentiation 1,33.  CYR61 is rapidly induced in response to mechanical stress or injury and has 
been implicated as a major player in the regulation of angiogenesis, matrix remodeling, and 
wound healing 34,39-42. 
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Although CYR61 can promote cellular proliferation in a variety of tissues, it is also 
known to activate apoptotic pathways in other cell types.  For example, studies have indicated its 
function in neural death via the JNK signal pathway as well as in the binding of integrins 33,43-45.  
In fibroblasts, CYR61 mediates cell adhesion by acting as a ligand of integrin αVβ3, and its 
transcription in these cells is rapidly activated by serum or purified platelet-derived growth factor 
without requiring de novo protein synthesis 34,37.  CYR61 upregulation in response to 
Coxsackievirus infection of human fibroblasts has also been found to enhance virus-mediated 
cell death 33.  
 While CYR61 expression can induce apoptosis in fibroblasts, its expression in some 
tumors has been correlated with a highly aggressive phenotype and functions as a poor 
prognostic indicator.  Its overexpression in a variety of malignancies – including those of the 
breast, prostate, and brain – correlates with a poor prognosis 1,33,46-49.  CYR61 has also been 
associated with accelerated tumor growth and vascularization in athymic nude mice in vivo 35.  
Overexpression of CYR61 in glioma cells has been observed to accelerate cellular growth and 
adhesion in vitro 34.  
 Preliminary studies in Dr. Kaur’s laboratory have revealed that CYR61 mRNA is induced 
in glioma cells of experimental rat brain tumors upon infection with oncolytic HSV-1.  Based on 
these results, we hypothesize that CYR61 mRNA transcription is induced following OV 
infection, both in vitro and in vivo, in a variety of cancerous glioma cell lines.  Furthermore, we 
hope to validate an increase in CYR61 protein expression in glioma cells after OV infection in 
vitro as well as in vivo.  These increases in CYR61 expression will confirm protein induction 
following OV infection and thereby signify that CYR61 overexpression in OV-treated tumors 
can be used as an indicator of virus survival and propagation.  This study may ultimately lead to 
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the development of CYR61 as a biomarker for evaluating the tumor oncolysis by HSV-1–derived 
OV. 
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 Materials and Methods 
Cells and Viruses 
 Human U343, U87, U87ΔEGFR, and LN229 glioma cell lines were maintained in 
Dulbecco’s modified minimal essential medium (DMEM) supplemented with 2% fetal Bovine 
serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin.  Rat glioma D74/HveC cells 
were derived from rat glioma D74 and were stably transfected with human HveC receptor to 
facilitate HSV infection 29.  These cells were maintained in Dulbecco’s modified minimal 
essential medium (DMEM) supplemented with 2% fetal Bovine serum (FBS), 100 U/ml 
penicillin, and 100 μg/ml streptomycin and 3.7 μg/ml blasticidin.  U87ΔEGFR cells express a 
truncated, constitutively active, mutant form of epidermal growth factor receptor (EGFR) and 
were maintained in DMEM supplemented with 2% fetal Bovine serum (FBS), 100 U/ml 
penicillin, and 100 μg/ml streptomycin and 200 μg/ml G418 50. 
Human patient tumor derived primary tumor cells were obtained from Dr. Akihiro Otsuki 
(Department of Neurological surgery, The Ohio State University).  These cells were grown as a 
monolayer in DMEM supplemented with 2% serum.  See Table 1 for details on the sources of 
these primary tumor cell lines. 
 We have been using HSV-1-derived oncolytic viruses: HSVQ, hrR3, rQNestin34.5, and 
rQ1-α-Fluc.  The genetic structure of wild type HSV-1 and the various OVs used in this study 
are shown in Figure 6.  hrR3 is a mutant of HSV-1-derived OV that lacks a functional ICP6 
gene, which codes for ribonucleotide reductase (RR), at the UL39 locus.  RR is essential for 
nucleotide synthesis required for DNA replication 11-14.  The absence of RR is compensated in 
cycling cancerous cells but not in normal non-dividing cells.  In hrR3, RR is disrupted by the 
insertion of an E. coli LacZ gene, resulting in the ability of the virus to replicate specifically in 
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Table 1: Sources of Patient-Derived Primary Tumor Cell Lines. 
Sources of primary tumor cell culture. 
 
Human patient tumor derived primary tumor cells were obtained courtesy of Dr. Akihiro Otsuki 
(Department of Neurological surgery, The Ohio State University).  In culture, the cells were 
grown as a monolayer in DMEM supplemented with 2% fetal bovine serum (FBS).  
Abbreviations: GMB - Glioblastoma multiforme; M - Male; F - Female; NA - Not applicable. 
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Schematic of wild type HSV-1 and the various HSV-1 derived oncolytic viruses used in this 
study. 
 
a:  HSV-1 genome structure showing the UL (Unique long sequences) and US (Unique small 
sequences).  Enlargements of the UL region depict the γ34.5 and ICP6 domains. 
 
b:  HSVQ is an HSV-1 derived virus with deletions of both γ34.5 genes, as well as the 
interruption of ICP6 by an insertion of EGFP.  This renders the virus unable to replicate in non-
dividing cells. 
 
c:  rQNestin34.5 is an HSVQ derived virus, in which one copy of the γ34.5 gene is reinserted 
into the UL39 locus under a Nestin promoter, making the virus more potent in Nestin positive 
glioma initiating cells. 
 
d:  Schematic of hrR3 virus, in which γ34.5 genes have been retained but ICP6 is interrupted by 
an insertion of LacZ. 
Figure 6: Schematics of HSV-1 Derivatives used in OV Treatment. 
a. HSV-1 TRL TRS 
UL US 
IRL IRS 
γ34.5 γ34.5ICP6 
c. rQNestin34.5  
Lox P FRT 
Nestin γ34.5ICP6 EGFPX 
Δ γ34.5 
X 
Δ γ34.5 
d. hrR3 ICP6 LacZ  
   γ34.5 
 
  γ34.5 
b. HSVQ 
Lox P FRT 
ICP6 EGFPX 
Δ γ34.5 
X 
Δ γ34.5 
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rapidly dividing glioma cells, such as those of a brain tumor, while leaving the host’s normal 
cells uninfected.  It also allows for easy visualization of infected cells by a simple staining for 
LacZ activity 3,11,51.   
HSVQ is also an HSV-1-derived OV that is deleted for both the copies of its γ34.5 gene, 
which is primarily responsible for the neurovirulence of the virus.  Additionally, insertion of 
EGFP within its UL39 locus results in disruption of ICP6/RR gene, further rendering the virus 
replication competent only in cycling cells 50.  The inserted EGFP is expressed under the control 
of the viral ICP6 promoter, allowing for easy visualization of infected cells by fluorescent 
microscopy.  rONestin34.5 is derived from HSVQ, in which one copy of the γ34.5 gene under 
the governance of glioma specific Nestin promoter is reinserted into the UL39 locus.  This makes 
the virus have more potent replication in Nestin positive glioma initiating cells  11,51.   
Animal Surgery 
 All animal experiments were performed according to the Subcommittee on Research 
Animal Care of The Ohio State University guidelines.  Fischer rats, aged 8 to 10 weeks, were 
purchased from Taconic (Taconic Farms, Germantown, NY) for in vivo study.  After the 
anesthetized rats were fixed in a stereotactic apparatus, a burr hole was drilled at 2 mm lateral to 
the bregma, to a depth of 3 mm.  Rat glioma D74/HveC cells (2 x 105 cells in 2 μl HBSS) were 
implanted as outlined 11.  One group of rats received an i.p. injection of CPA (Bristol-Myers 
Squibb, Princeton, NJ) five days after tumor implantation at a dose of 80 mg/kg of phosphate 
buffered saline (PBS).  Seven days after tumor cell implantation, anesthetized rats were 
stereotactically inoculated with 1 x 107 P.F.U of rHSVQ suspended in 5 μl HBSS at the same 
coordinates.  Animals were closely monitored for any signs of morbidity, and were euthanized 
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three days after infection.  Tumor-bearing right hemispheres were excised and processed for 
RNA as described. 
 Athymic nude mice, aged 6 to 8 weeks, were purchased from Charles River Laboratories 
(Charles River Laboratories, Inc., at NCI-Frederick Animal Production Area, Frederick, 
Maryland) for in vivo study.  After the anesthetized mice were fixed in a stereotactic apparatus, a 
burr hole was drilled at 2 mm lateral to the bregma, to a depth of 3 mm.  Human glioma 
U87ΔEGFR cells (2 x 105 cells in 2 μl HBSS) were implanted as outlined 11.  Ten days after 
tumor cell implantation, anesthetized mice were stereotactically inoculated with 1 x 107 P.F.U. of 
rHSVQ suspended in 5 μl HBSS at the same coordinates.  Animals were observed daily and were 
euthanized three days after infection.  Tumor-bearing right hemispheres were excised and 
processed for RNA as described. 
Immunofluorescence Staining 
 Brains from sacrificed animals were extracted and fixed in 4% paraformaldehyde (PFA).  
After being dehydrated in 30% sucrose, the brains were frozen in an isopropanol dry-ice bath.  
Frozen brains were then sectioned to a thickness of 10 μm by cryostat (LEICA CM3050S).  The 
brain sections were thawed and rehydrated in PBS prior to staining.  10% normal goat serum 
(NGS) was used to block endogenous proteins and peroxidases by incubation at room 
temperature for 1 hour.  Tissue sections were washed in PBS and then incubated for 1 hour at 
room temperature in goat α-rabbit IgG-Alexa 546, a conjugated primary antibody (1:200 dilution 
in PBS) (Molecular Probes, #A11034).  This antibody is conjugated to a fluorescent agent, so 
that when it binds to the antigen of interest – in this case CYR61 – the antigen’s presence can be 
visualized by fluorescent confocal microscopy.  The brain sections were washed again in PBS 
and then incubated for 30 minutes at room temperature and in the dark in DAPI (1:10,000 
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dilution in PBS) (Sigma, #D8417).  DAPI binds strongly to DNA and is thus useful for 
visualizing cellular density in tumor areas.  DAPI fluorescence acts as a control for analyzing the 
antigen of interest.  After another wash in PBS, the slides were fixed using Prolong™ Antifade 
Kit (Molecular Probes, #P7481). 
RNA Preparation 
Each 10 cm plate of cells in vitro was washed twice with 3 ml PBS.  In an RNAase-free 
hood, 2 ml of Trizol reagent (Invitrogen, #15596-026) was added to each plate.  This reagent 
allows the RNA to remain intact while dissolving other cell components.  After 5 minutes of 
shaking at room temperature, the suspension was transferred to two 1.5 ml Eppendorf tubes.  200 
μl chloroform was added to each tube to separate the aqueous and organic phases.  The tubes 
were then shaken vigorously by hand for 15 seconds, rested for 3 minutes, and centrifuged at 
16.3 x 1000 g for 15 mins at 4°C.  After centrifugation, 3 phases were visible; the bottom organic 
phase contained most of the cellular proteins, the intermediate interphase contained cellular 
DNA, and the top aqueous phase contained cellular RNA.  The RNA was precipitated from the 
aqueous phase by adding 1 ml isopropanol, followed by centrifugation at 16.3 x 1000 g at 4°C.  
The resulting RNA pellet was washed with 2 ml 75% ethanol, followed again by centrifugation 
at 16.3 x 1000 g for 10 minutes at 4°C.  The air-dried pellet was resuspended in 25 μl of 
Ultrapure water. 
In vivo samples were prepared by sectioning the brain after sacrificing the animal to 
isolate the tumor area.  The tumor samples were then treated with 2 ml Trizol reagent and 
homogenized by syringe.  The samples were then treated with 200 μl chloroform, centrifuged, 
and RNA was precipitated as outlined above.     
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Isolated RNA was cleaned using an RNeasy Mini Kit (Qiagen, #74104) according to the 
manufacturer’s instructions.  Briefly, a mixture of Cellular RNA, RLT lysis buffer, ethanol and 
β-mercaptoethanol was applied to an RNeasy mini spin column and centrifuged at 10,000 rpm 
for 15 seconds.  The spin columns were washed with 350 μl Buffer RW1 and then treated with 
DNase I for 15 minutes at room temperature, followed by three more washes.  Finally, RNA was 
eluted in 30-50 μl RNase-free water and was quantified. 
cDNA Synthesis 
cDNA was made following a standard protocol as described by SuperScript™ First-
Strand Synthesis System for RT-PCR (Invitrogen, 11904-018).  Briefly, 5 μg of purified RNA 
was incubated with 1 μl 10mM dNTP mix, 1 μl Oligo(dT)12-18(0.5 μg/μl), and 10 μl DEPC-
treated water at 65°C for 5 minutes, and then was placed on ice for 1 minute.  A reaction mixture 
consisting of 2 μl 10x RT buffer, 4 μl 25 mM MgCl2, 2 μl 0.1 M DTT, and 1 μl RNaseOUT™ 
Recombinant RNase Inhibitor was added to an aliquot of the RNA/primer mixtures, which were 
then mixed gently and centrifuged briefly.  The samples were incubated for 2 minutes at 42°C.  
Then, 1 μl (50 units) of SuperScript™ II RT (Invitrogen, 11904-018) was added to each tube, 
mixed, and allowed to incubate for 50 minutes at 42°C.  The reactions were terminated by 
incubation at 70°C for 15 minutes and were then chilled on ice briefly.  Each reaction was 
incubated with 1 μl of RNase H, after which the tubes were incubated for 20 minutes at 37°C. 
Quantitative Real-Time PCR (QRT-PCR) 
Quantitative Real-Time PCR (QRT-PCR) was performed to confirm the up-regulation of 
CYR61 upon virus infection by analyzing the cDNA derived from infected cells.  Real-time 
continuous detection of PCR product is facilitated by monitoring the increase in fluorescence of 
SYBR Green, which binds to the double stranded DNA generated during each cycle of the PCR 
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reaction.  This fluorescence is quantified to determine relative amounts of DNA in the initial 
sample.  Briefly, to each well of a 96-well plate, 2.5 μl of the indicated forward and reverse 
primers, 2.5 μl Ultrapure water, 12.5 μl SYBR Green (Applied Biosystems, #4304437), and 5 μl 
cDNA sample was added.  The reaction plate was sealed and centrifuged for 3 minutes at 1200 
rpm and QRT-PCR was performed using a 7500 real-time PCR system (Applied Biosystems, 
Foster, CA).  Samples were amplified in triplicate.  Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and β-actin were used as internal controls for all human and rat samples, respectively.  
Relative quantification of gene expression was calculated as a ratio of the difference in the 
number of cycles needed for expression of a gene in a tumor from untreated and treated rats.  
The formula used was 2dCt CYR61/2dCt control, where Ct is the number of cycles for saturation 
and dCt is the difference between the number of cycles needed for expression of a gene in a 
tumor from untreated rats (used as a baseline) and for expression from rats receiving treatment 
(tumor or tumor plus virus). 
Primers for LacZ, β-actin, GAPDH, and CYR61 were designed with the Primer Express 
Program (Applied Biosystems) (Table 2). 
Agarose Gel Electrophoresis 
 Agarose gel electrophoresis was used to confirm the fidelity of QRT-PCR reactions.  A 
1.5% agarose gel was made in 1x TAE.  2 μl ethidium bromide was added to the dissolved 
agarose, after which the gel was poured and allowed to set.  The samples were prepared by 
adding 2 μl orange dye to 10 μl of the QRT-PCR sample.  The gel was run at 100 V.   
Harvesting Cells in Culture 
 The conditioned medium was harvested and cleared of cellular debris by centrifugation at 
4000 rpm for 10 minutes.  The resulting supernatant was stored at -20°C.  Cells were harvested
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Primer Primer sequence Species 
Sense 5’ – AAT GGC TTT CGC TAC CTG – 3’ 
LacZ 
Antisense 5’ – CCA TCG CGT GGG CGT A – 3’ 
E. Coli 
Sense 5’ – CTA CAG ATC ATG TTT GAG ACC TTC AAC – 3’ 
β-actin 
Antisense 5’ – CCA GAG GCA TAC AGG GAC AAC – 3’ 
Rat 
Sense 5’ – GGA GTC AAC GGA TTT GGT CG – 3’ 
GAPDH 
Antisense 5’ – GGA ATC ATA TTG GAA CAT GTA AAC C – 3’ 
Human 
Sense 5’ – AGA GGT GTT GAG CAT CGT GGA G – 3’ 
Antisense 5’ – AAC TGC GAC TGC GTT ACT GTC C – 3’ 
Rat 
Sense 5’ – AAT GGA GCC TCG CAT CCT ATA – 3’ 
CYR61 
Antisense 5’– TTC TTT CAC AAG GCG GCA – 3’ 
Human 
Table 2: Primers Used in QRT-PCR Analysis. 
Sequences of primers used in QRT-PCR analysis. 
 
Primers for LacZ, a protein encoded by the mutant OVs, were used to evaluate viral presence in 
tissue samples taken from OV treated tumors in a rat glioma model.  Rat β-actin primers were 
used to quantify actin expression in cell lysate samples, and were thus used as an internal control 
in evaluating CYR61 in rat glioma cell lines in vitro and in vivo.  Similarly, human GAPDH was 
used as an internal control for samples derived from human glioma cell lines in vitro and in vivo.  
CYR61 was used to assess CYR61 expression in both rat and human cell lines, in vitro and in 
vivo, and thus primers produced in both species were used in this study. 
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by lysing cells in lysis buffer (8M Urea, 4% SDS, and protease inhibitor cocktail tablet 
[Complete Mini, #11 836 153 001]).  A rubber policeman was used to scrape the cells, and the 
cell lysate samples were also stored at -20°C.  After cell harvest, tissue culture plates were 
incubated with lysis buffer at 85°C for 1 hour to harvest the insoluble, plate-bound extracellular 
matrix (ECM).  The conditioned medium and ECM were further concentrated by Trichloroacetic 
acid (TCA) precipitation. 
TCA Precipitation 
 Trichloroacetic acid (TCA) is a strong acid that effectively precipitates proteins, DNA, 
RNA and other macromolecules from harvested samples.  TCA precipitation was used to 
concentrate proteins from dilute CM and ECM samples, as well as to remove TCA soluble 
impurities.  50% ice cold TCA was added until the final TCA concentration was 15% in the 
conditioned medium or ECM.  The samples were incubated on ice for 30 minutes, followed by 
centrifugation at 10,500 g for 30 minutes at 4°C.  The pellets were washed twice with 1 ml of ice 
cold acetone and then centrifuged for 20 minutes (same as before).  Air-dried pellets were 
rehydrated and resuspended in urea lysis buffer.  Cell lysates were sonicated and then 
centrifuged at 12,000 rpm for 8 minutes.  After protein quantification, these samples were 
evaluated for protein content by Western Blot analysis. 
SDS Preparation of In Vivo Samples 
 After removing the brain from the sacrificed animal, the tissue sample was suspended in 
an equal weight of RIPA buffer (150 mM NaCl in 40 ml, 1% Nonidet P-40, 0.5% Sodium 
deoxycholate, 0.1% SDS, 150 mM Tris, protease inhibitor cocktail tablet [Complete Mini, #11 
836 153 001]; pH = 8.0).  The samples were homogenized by syringe and centrifuged (10,000 g, 
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10 minutes at 4°C).  The supernatant was decanted to assess protein content by Western Blot 
analysis following protein quantification. 
Protein Quantification 
 To quantify the protein content of each sample, an RC DC Protein Assay kit was used to 
perform a microfuge tube assay according to the manufacturer’s instructions (Bio-Rad, #500-
0119).  Briefly, 3-5 dilutions of a protein standard were prepared from 0.2 mg/ml to 1.5 mg/ml 
protein, 25 μl of which was pipetted into clean microfuge tubes.  The protocol was modified by 
adding 25 μl of RC Reagent I to each tube.  These tubes were then vortexed and incubated at 
room temperature for 1 hour.  The protocol was modified again when 25 μl RC Reagent II was 
added to the samples, which were then vortexed and centrifuged at 15,000 g for 3-5 minutes.  
The supernatant was discarded, and the precipitate was dissolved in 25.4 μl of Reagent A’ (5 μl 
DC Reagent S, 250 μl DC Reagent A).  The tubes were incubated at room temperature for 5 
minutes, and vortexed briefly.  To each tube was added 200 μl DC Reagent B, followed 
immedatiately by vortexing and incubation at room temperature for 15 minutes.  The 
absorbances were then read at 750 nm. 
Western Blot Analysis 
Equal amounts of protein from the soluble supernatant was added to 6x SDS loading 
buffer (1 μl loading buffer : 5 μl cell sample).  The prepared samples were denatured and 
reduced by boiling at 95°C for 4 minutes in the presence of reducing SDS dye.  The samples 
were resolved by polyacrylamide gel electrophoresis in a Criterion precast gel (Bio-rad, #345-
0009) to separate the proteins based on molecular weight.  After electrophoresis, the proteins 
were transferred to a PVDF transfer membrane (Immobilon, #IPVH 20200) by electroblotting, in 
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which an electric current moves the proteins from the gel to the membrane.  Transfers were 
completed at 220 mAmps. 
 Membranes were blocked in 5% non-fat milk in PBST 0.1% (block buffer) overnight at 
4ºC, to inhibit non specific interactions between the membrane and the chosen antibodies.  
Primary antibody, which binds to the protein of interest on the membrane, was diluted in block 
buffer and applied to the membranes for 1 hour.  The membranes were then washed three times 
for five minutes in PBST 0.1% to remove unbound and nonspecifically bound primary antibody.  
The membranes were incubated with a secondary antibody (also diluted in block buffer) that was 
raised against the primary and conjugated to horseradish peroxidase to facilitate detection.  
Because multiple secondary antibodies can bind to a single bound primary, this step results in 
amplification of the signal.  The membranes were washed three times for 10 minutes in PBST 
0.1% to remove unbound and nonspecifically bound antibodies.  The membranes were developed 
using ECL Western Blotting Detection System (Amersham Biosciences, #RPN2132).  This 
system contains a substrate that luminesces upon reacting with a reporter on the secondary 
antibody.  As a result, relative amounts of protein can be determined by comparing the 
luminescence of the samples. 
 To probe for CYR61, pAb anti-CYR61 (Rabbit) (Novus Biologicals, #NB100-357) in a 
1:750 dilution of 5% blocking milk was used for the primary antibody.  The secondary antibody 
was Polyclonal Goat Anti-Rabbit Immunoglobulins/HRP (Dakocytomation, #P0448) in a 
1:1,000 dilution of PBST 0.1%. 
 To probe for β-actin, Monoclonal Anti β-actin antibody produced in mouse (Sigma, 
#A1978-200) in a 1:2,000 dilution of 5% blocking milk was used for the primary antibody.  The 
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secondary antibody was ECL Anti-Mouse IgG, horseradish peroxidase linked whole antibody 
(from sheep) (Amersham Biosciences, #NA931V) in a 1:20,000 dilution of PBST 0.1%. 
Microvessel Density Quanitification 
 Following tumor implantation (Day 0) and OV infection (Day 7), the rats were monitored 
for signs of morbidity.  Five minutes prior to euthanization, the rats were injected by tail vein 
with 0.25 ml of 1 mg/ml fluorescein isothiocyanate-dextran (FITC-dextran; >60 kDa) (Sigma-
Aldrich, MO).  FITC-dextran remains within blood vessels, thereby highlighting the animal’s 
functional, perfused blood vessels.  After removing and sectioning the brains of sacrificed 
animals, the entire tumor section was scanned microscopically at a low magnification (4x) to 
identify hotspots, or areas of high vascularization.  The individual tumor microvessels that 
comprise these hotspots were then counted under high magnification (20x) to obtain a vessel 
count in a defined area.  Microvessel density was defined as the average of 3 distinct hotspot 
vessel counts.  Microvessel counting was performed in multiple tumor sections (n = 5 
rats/group). 
Statistical Analysis 
 The statistical analysis appearing in figure legends was obtained using Student’s t-test 
and Wilcox’s test.  P-values less than 0.05 were considered significant, and data was presented 
as the mean +/- standard deviation.   
 The relative value of each QRT-PCR group was compared using a one-way ANOVA 
followed by a Scheffe´ post hoc test.  Significance was assumed if the P-value was less than 
0.05.  Again, data was presented as the mean +/- standard deviation. 
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Results 
 
Transcript Profiling Reveals Induction of CYR61 mRNA in Rat Glioma Tumors Treated 
with Oncolytic hrR3 
 Initial studies of the temporal presence of OV in rat brain tumor models revealed that the 
virus was cleared rapidly from tumor tissue by innate immune responses elicited upon infection 
29,52-54.  Apart from host immune responses, recent studies have also underscored the significance 
of tumor microenvironment as a limitation to viral spread 23,24.  We believe that changes in tumor 
microenvironment will have a very significant impact on OV therapy.   
 To understand the changes in tumor environment, Dr. Kaur’s laboratory has been 
evaluating the transcript profiling of tumors treated with OV.  The laboratory has exploited CPA 
enhancement of OV therapy to understand the changes in gene expression tumors that occur after 
OV treatment in a syngeneic rat glioma model.  Transient immune suppression of animals by 
CPA treatment prior to OV therapy results in increased viral presence in tumor tissue.  The 
increased viral persistence enables greater tumor destruction and, thus, increases the therapeutic 
efficacy of the OV 28,29.  The experimental protocol is detailed in “Materials and Methods.”  
Briefly, five days following intracerebral tumor implantation (2 × 105 D74/HveC rat glioma 
cells), rats were treated with an intraperitoneal injection of CPA or PBS (control), followed by an 
intratumoral injection of hrR3 virus on Day 7.  The rats were sacrificed and brain tumors 
harvested at 12 and 72 hours after OV infection.  RNA from these samples was isolated and 
converted to cDNA, which was then analyzed by gene chip assay (Affymetrix Genechip Rat 
Genome 230 2.0 Array) (Figure 7a).  Using over 31,000 probe sets, this array analyzed for more 
than 30,000 transcripts and over 28,000 rat genes. 
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Microcluster Analysis via gene chip QRT-PCR reveals up regulation of CYR61 72 hours 
post infection of rat glioma tumors. Viral presence at 72 hours post infection is confirmed 
by agarose gel electrophoresis of virally encoded LacZ QRT-PCR product. 
 
a:  Gene chip QRT-PCR microcluster analysis of genes dysregulated by CPA pretreatment in 
rat brain tumors harvested 12 and 72 hours post hrR3 infection.  Animals were pretreated with 
PBS/CPA 5 days after tumor implantation, and treated with hrR3 virus on day 7.  Total RNA 
from tumors was harvested 12 and 72 hours after OV treatment, and changes in gene expression 
were evaluated by Affymatrix gene chip analysis.  Upregulation is shown in red, 
downregulation in green, and no change in black.  Note the upregulation of CYR61 mRNA in 
CPA treated animals at 72 hours, but not 12 hours, post infection. 
 
b:  Verification by Agarose gel electrophoresis of QRT-PCR product of OV encoded LacZ in 
animals treated with PBS/CPA on day 5 after tumor implantation, followed by OV infection on 
day 7.  12 hours post OV infection, no difference is observed between samples treated with PBS 
and CPA (lanes 1-3 versus 4-6).  72 hours post infection, however, rapid clearance of PBS is 
contrasted with sustained OV presence in CPA pretreated animals (lanes 7-9 versus 10-12).  β-
actin probes for actin, a protein found in most mammalian cells, and is used here as a control. 
a. 
b. 
Figure 7: Transcript Profiling of Rat Glioma Tumors Treated with 
OV and CPA Revealed a Significant Induction of CYR61. 
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 Figure 7b represents RT-PCR analysis for LacZ encoded by the OV.  Note that at early 
time points (12 hours) post OV therapy, the presence of OV is not significantly changed in tumor 
tissue derived from either control PBS-treated or CPA-treated rats (compare lanes 1-3 with 4-
6).  However, at 72 hours post infection, the rapid clearance of OV in PBS-treated animals is 
notable compared to the sustained presence of virus in animals pretreated with CPA (compare 
lanes 7-9 with 10-12).  This persistent viral presence in CPA-treated animals correlates with the 
upregulation of CYR61 seen in the microcluster analysis at 72 hours post infection. 
The observation of increased CYR61 mRNA in the tumor tissue of CPA-treated rats 72 
hours after OV therapy was very interesting because: 
1. The induction of CYR61 mirrored the presence of virus in the tumor tissue, 
which indicated that CYR61 might be exploited as an interesting 
biomarker for OV therapy.     
2. CYR61 is a secreted extracellular matrix protein known to play a very 
important role in tumor progression.   
Confirmation of CYR61 Induction by Quantitative Real-Time PCR (QRT-PCR) Analysis 
We used Quantitative RT-PCR to confirm the induction of CYR61 in rat brain tumors 72 
hours post infection with OV.  We formed four test treatment groups of nine animals each: 
control (PBS treated), CPA only, OV only, and CPA + OV.  The animals were treated with 
PBS/CPA 5 days after tumor implantation.  Two days after this treatment (Day 7 after tumor 
implantation), PBS/hrR3 virus was administered by direct intratumoral injection.  The animals 
were sacrificed, and total RNA from brain tumor tissue was harvested 72 hours after infection.  
These samples were then analyzed by QRT-PCR with primers for CYR61 and β-actin (Figure 
8a).  The fold-induction of CYR61 over actin in each sample was calculated.   
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QRT-PCR and scatter plot analyses reveal a compelling correlation between viral 
presence and CYR61 mRNA expression at 72 hours post infection. 
 
a:  QRT-PCR for CYR61 gene expression in rat brain tumors 72 hours after PBS/OV treatment 
(n=9/group).  After tumor implantation, animals were pretreated with PBS/OV on day 5, and 
PBS/OV on day 7.  72 hours after infection the animals were sacrificed.  Control and CPA 
groups show no significant induction of CYR61, while animals treated with OV only show 
slight induction.  Note that the significant increase in CYR61 gene expression in animals treated 
with both CPA and OV correlates to the previously observed prolonged viral presence in CPA 
pretreated animals.   
 
b:  Scatter plot analysis of the LacZ and CYR61 QRT-PCR product of the same rat glioma 
tumors, both with and without CPA pretreatment (n=18).  The graph reveals significant positive 
correlation between CYR61 and virally encoded LacZ expression, indicating CYR61 induction 
is association with increased viral presence.   
Figure 8: QRT-PCR Results Indicate a Correlation between CYR61 
Induction and OV in Rat Brain Tumors. 
a.
b.
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 The results show mean expression of CYR61 in tumor tissue derived from all the animals 
in each group (n = 9/group).  CYR61 expression was not significantly induced in animals that 
did not receive OV treatment (PBS- or CPA-treated).  Tumor tissue obtained from animals 
treated with only OV showed slight induction of CYR61 (7.5-fold-induction over actin).  This 
induction was significantly enhanced in tumor tissue obtained from OV-treated animals that were 
pretreated with CPA (17.5-fold-induction over actin; P < 0.05 for induction over OV-only 
group).  Because our previous findings show that viral clearance is inhibited by CPA 
pretreatment, we can infer that CYR61 mRNA induction is correlated to the ongoing presence of 
OV in these animals.   
Correlation between CYR61 Induction and hrR3 in Rat Brain Tumors 
 To test the significance of this perceived correlation between CYR61 expression and viral 
presence in tumors, we performed scatter plot analysis of virally encoded LacZ and CYR61 
expression in each OV-infected tumor tissue (Figure 8b).  The scatter plot analysis included 
animals treated with and without CPA whose brain tumors were harvested 72 hours post 
infection (n = 18).  Animals pretreated with PBS are concentrated to the left of the graph, where 
LacZ expression is low.  These animals also exhibit low expression of CYR61.  Similarly, 
animals pretreated with CPA consequently express high amounts of LacZ and express a large 
amount of CYR61.  Thus, the scatter plot reveals a compelling correlation between CYR61 and 
virally encoded LacZ mRNA expression and gives further evidence of the association between 
CYR61 induction and viral presence (R = 0.638, P < 0.05). 
Induction of CYR61 upon hrR3 Infection of Glioma Cells in Vitro 
Solid tumors are very complex tissue that comprises tumor cells and normal fibroblasts as 
well as inflammatory cells, endothelial, and pericyte cells embedded in a complex extracellular 
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matrix.  The CYR61 mRNA in tumor tissue could result from OV-induced infiltration into tumor 
tissue that expresses CYR61.  However, the positive correlation observed between CYR61 
expression and OV presence, irrespective of whether animals were immune suppressed with 
CPA pretreatment, highlighted the possibility that CYR61 may be induced directly upon OV 
infection of tumor tissue. 
 We tested this by evaluating changes in CYR61 expression in glioma cells infected with 
OV in vitro.  1 × 106 D74/HVeC rat glioma cells were plated in 10-cm dishes and infected 24 
hours later with hrR3 virus (MOI = 0.05).  The cell lysates were harvested at 0, 4, 8, and 24 
hours post infection.  Total RNA was isolated and converted to cDNA, as described in 
“Materials and Methods.”  cDNA derived from the rat glioma cells was then analyzed for 
CYR61 and actin expression by QRT-PCR.  Samples were standardized with β-actin; our results 
show the fold-induction over actin expression.  The results indicated a significant and early 
increase in CYR61 mRNA expression after OV infection (Figure 9).  Expression increased from 
0 to 4 hours post infection, and very slightly from 4 to 8 hours.  In the interval between 8 and 24 
hours, however, CYR61 expression increased significantly.  The HSV lytic cycle is about 12 to 
16 hours, and this upsurge in CYR61 expression coincides with the viral burst.  Hence, this 
increase at 24 hours after initial infection may represent increased infection from the second 
amplified round of viral progeny released after the first round of replication.  This may indicate a 
dose-response relationship between CYR61 induction and viral infection.   
Induction of CYR61 in Glioma Cells upon Infection by Three Different HSV-1-Derived 
OVs in Vitro 
 Next, we tested if induction of cellular CYR61 could be reproduced by infection of 
glioma cells with different OVs.  To do this, we employed three different HSV-1-derived OVs: 
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Time course QRT-PCR analysis reveals induction of Cyr61 mRNA upon OV infection of 
D74 rat glioma cells in vitro. 
 
a:  D74 cells were infected with hrR3 in vitro, and cell lysates were harvested 0, 4, 8, and 24 
hours post infection.  Following RNA isolation and cDNA synthesis, the samples were analyzed 
for CYR61 expression via QRT-PCR.  The results were standardized by evaluating CYR61 
fold-induction over actin expression in each sample.  Note the increase in level of CYR61 
mRNA expression at each time point.  Furthermore, the magnitude of the increases in CYR61 
expression correspond to the viral life cycle, thereby providing further evidence for CYR61’s 
induction upon OV infection. 
 
b:  The same data has been normalized to uninfected cells, showing the fold-induction of 
CYR61 expression in infected cells.
Figure 9: Induction of CYR61 upon OV Infection of Glioma Cells, 
in Vitro. 
a.
b.
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hrR3, HSVQ, and rQNestin34.5.  The structures and genetic mutations of each of these viruses 
are detailed in “Materials and Methods” and in Figure 6.  1 × 106 D74/HVeC rat glioma cells 
were plated in 10-cm dishes and infected 24 hours later with the indicated OV (MOI = 0.05).  
The cell lysates were harvested 30 hours after infection, and total RNA was isolated and 
converted to cDNA as described in “Materials and Methods.”  The cDNA was evaluated for 
CYR61 expression by QRT-PCR, as described.  Again, the samples were standardized by 
calculating the fold-induction over actin expression in each RNA sample.  Note the significantly 
increased level of CYR61 in samples infected with hrR3, HSVQ, and rQNestin34.5 in 
comparison to uninfected cells (Figure 10).  These results indicate that CYR61 is induced in 
response to OV infection and is not a response specific to the previously tested hrR3 virus. 
Induction of CYR61 mRNA upon OV Infection in Human Glioma Cells in Vitro 
 These results indicated a rapid and significant induction of CYR61 after OV infection of 
rat D74/HveC glioma cells in vitro.  Next, we evaluated if CYR61 mRNA would be similarly 
induced in human glioma cells after infection with HSV-1-derived OV.  We tested this in human 
glioma cell lines (LN229, U343, U87, and U87ΔEGFR) and in primary tumor cells from patient 
biopsy.  These cells are curated by the Dardinger Laboratory at The Ohio State University and 
were obtained from Dr. Otsuki.  The tumor characteristics of these patient-derived tumor cells 
are described in “Materials and Methods” and in Table 1.  On Day 0, 1 × 105 of the indicated 
cells were plated in a 10-cm dish.  The cells were treated with PBS or rQNestin34.5 virus on Day 
1 (MOI = 1).  Total cellular RNA was isolated 24 hours after infection, converted to cDNA, and 
was analyzed by QRT-PCR as described in “Materials and Methods.”  GAPDH served as an 
internal control, resulting in data that reflects CYR61 expression as a fold-induction over 
GAPDH expression in each sample.  The data were normalized to the levels of CYR61 in a 
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Figure 10: Induction of CYR61 in Glioma Cells upon Infection by 
Various HSV-1-Derived OVs, in Vitro.   
The upregulation of CYR61 mRNA 30 hours post infection of D74 rat glioma cells in vitro 
using three different HSV-1 derived OVs. 
 
D74 rat glioma cells were infected with the hrR3, HSVQ, or rQNestin34.5 in vitro.  Cell lysates 
were harvested 30 hours post infection.  Isolated RNA was converted to cDNA, after which the 
samples were analyzed by QRT-PCR.  The results were standardized by evaluating CYR61 fold-
induction over actin expression in each sample.  Note the significantly increased level of CYR61 
mRNA expression in each of the three OVs when compared to the uninfected sample.  
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normal brain sample obtained from an epileptic lobectomy.  The fold-induction of infected cells 
over uninfected cells for each cell line indicated a significant increase in CYR61 mRNA 
expression in all the cell lines tested (Table 3).  The increased levels of CYR61 mRNA 
expression upon OV infection in each tumor cell line provide evidence that CYR61 induction is 
a direct result of OV infection and occurs in a wide variety of human glioma cells. 
Induction of CYR61 Protein Expression upon OV Infection of Human Glioma in Vitro 
To evaluate if induction of CYR61 mRNA also translated into increased levels of protein 
after HSV infection, we evaluated changes in levels of CYR61 protein after infection with OV in 
vitro.  U343 human glioma cells were infected with either hrR3 (MOI = 0.1) or PBS.  The cells 
were harvested 16 hours after infection, and the amount of CYR61 in cell lysate and ECM was 
evaluated by Western blot analysis, as detailed in “Materials and Methods.”  The results indicate 
an increase in both the secreted full length and proteolytically processed form of CYR61 in the 
ECM of OV-infected cells (Figure 11a).  Plasmin cleavage of CYR61 has previously been 
shown to liberate CYR61 protein from the ECM, and thereby plays a role in many of CYR61’s 
pathophysiologic processes involved in tumor growth and angiogenesis 55.  Our findings also 
show an increase in CYR61 protein in the cell lysate after OV infection.  The membrane was 
also probed for actin as an internal control, which reveals that CYR61 expression is also 
significantly upregulated in the cell lysate (Figure 11b). 
Induction of CYR61 Protein Expression upon OV Infection of Human Glioma in Vivo 
Next, we investigated if CYR61 protein induction is observed in vivo.  U87ΔEGFR 
human glioma cells were implanted in athymic nude mice by intracerebral injection.  The 
animals were injected intratumorally with either OV or PBS on Day 7 following implantation,
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Induction of CYR61 upon OV infection is confirmed in multiple human glioma and 
patient derived tumor cell lines. 
 
The listed human glioma cell lines and patient derived tumor cells were each treated with PBS 
or rQNestin 34.5 for 24 hours (MOI = 1).  The cells were the harvested and analyzed by QRT-
PCR.  The samples were analyzed for the amount of CYR61 relative to the amount of GAPDH 
(an internal control) expressed by the cells.  The results were normalized to the levels in a 
normal brain.  Note the induction of CYR61 mRNA expression upon OV infection in each 
tumor cell line. 
Table 3: Induction of CYR61 mRNA upon OV Infection in Several 
Human Glioma Cells, in Vitro. 
 46
Figure 11: Induction of CYR61 Protein in Vitro after Infection of 
Human Glioma Cells.   
Western blot analysis reveals induction of CYR61 protein in vitro upon infection of human 
glioma U343 cells.   
 
a:  U343 human glioma cells were infected with either hrR3 or PBS.  After 16 hours of 
infection, the ECM was harvested and evaluated for CYR61 expression by western blot analysis.  
Note the substantial increase in CYR61 protein secreted into the ECM in cells treated with 
HSV-1-derived OV over those treated with PBS.  ∗Indicates a proteolytic fragment of CYR61 
56. 
 
b:  From the same samples, cell lysates were also harvested that display an increase CYR61 
expression relative to actin expression in cells treated with hrR3.  
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and tumors were harvested at 24 and 48 hours after infection.  These tissue samples were 
evaluated for CYR61 expression by Western blot analysis and were normalized to actin 
expression.  The results clearly indicate an increase in CYR61 protein expression in infected 
cells when compared to the uninfected sample (Figure 12). 
 We also assessed in vivo CYR61 protein induction by immunofluorescence staining.  
U87ΔEGFR human glioma tumor cells were implanted to form intracerebral tumors in athymic 
nude mice, as described.  Seven days after tumor implantation, the tumors were treated with 
PBS/rQNestin34.5 by direct intracerebral injection.  The mice were euthanized and the tumors 
harvested at 72 hours post infection.  The tissue samples were then stained for CYR61 and DAPI 
expression (Figure 13).  DAPI, which stains for cellular nuclei, allows visualization of cell 
density.  Highly dense DAPI fluorescence represents areas of high cellular density, or areas of 
tumor.  A comparison of the tumor edge as depicted by stainings for DAPI and for CYR61 
reveals that very little CYR61 is expressed in the PBS-treated control group.  In contrast, 
staining for CYR61 in the OV group reveals significant induction of CYR61 protein expression.  
Furthermore, this protein expression is localized to the tumor region; the tumor edge, as depicted 
by DAPI staining, matches that of the boundary of CYR61 expression for the tumor treated with 
OV.  These results indicate that CYR61 protein expression is also induced upon OV infection in 
the athymic nude mouse model in vivo.    
Induction of Angiogenic Inducer CYR61 upon OV Treatment Leads to Increased 
Microvessel Density of the Residual Disease 
CYR61 is known to be a potent angiogenic inducer 34,38,47,56.  Furthermore, elevated 
levels of CYR61 are sustained after blood vessel formation in endothelial cells, suggesting that 
the protein also functions in vessel maintenance.  Studies have also shown that CYR61 plays a
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Figure 12: Induction of CYR61 Protein in Vivo after OV Infection 
of Human Glioma Cells. 
Western blot analysis reveals induction of CYR61 protein in vivo upon infection of human 
glioma U87ΔEGFR cells.   
 
U87ΔEGFR human glioma cells were implanted in athymic nude mice by intracerebral injection.  
On Day 7, either OV or PBS was administered intratumorally.  The animals were sacrificed and 
brain tissues harvested 24 and 48 hours after infection.  Using western blot analysis, the samples 
were evaluated for CYR61 expression (45 kDa) relative to actin expression (44 kDa).  The 
results show a considerable increase in CYR61 protein expression in OV treated tumors in 
comparison to uninfected tumors in vivo. 
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Immunofluorescence staining for CYR61 protein expression reveals induction of CYR61 
protein upon OV infection of intracerebral tumors in athymic nude mice. 
 
Intracerebral brain tumors (U87ΔEGFR cells) were implanted in athymic nude mice.  These 
tumors were treated with either PBS (control group) or rQNestin34.5 (OV group) on day 7.  72 
hours post infection, the mice were sacrificed and the harvested tumors were analyzed for 
CYR61 and DAPI protein expression by immunofluorescence staining.  DAPI depicts cellular 
density; the edges of tumor regions are visible in these stainings.  The CYR61 staining 
corresponding to these frames reveals a significant induction of CYR61 protein expression upon 
OV infection.  Furthermore, the CYR61 protein is localized to the tumor region in the tumor 
treated with OV, thus giving further evidence of CYR61’s association with viral presence. 
Figure 13: Induction of CYR61 Protein Expression upon OV 
Infection of Intracerebral Tumors in Athymic Nude Mice. 
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significant role in neovascularization in vivo 34.  We therefore hypothesized that an increase in 
secreted levels of CYR61 protein in a tumor’s extracellular matrix after oncolysis would lead to 
increased angiogenesis of the residual disease.  This could lead to an aggressive recurrence of the 
tumor and may contribute to the reduced efficacy of OV observed in clinical trials. 
 We tested this by comparing the microvessel density of untreated and OV-treated size-
matched tumors in the rat glioma model.  PBS-treated (mean survival, Day 14) and hrR3-treated 
(mean survival, Day 21) animals were sacrificed upon showing signs of morbidity.  Five minutes 
prior to euthanization, the rats received tail-vein injections of dextran conjugated to FITC (> 
60kDa).  This compound was used to stain perfused or circulating blood vessels in the tumor 
region.  A comparison of size-matched tumors derived from control PBS-injected animals 
(original disease) and tumors from animals treated with OV (recurrent disease) showed an 
increase in microvessel density (Figure 14a).  Quantification of the number of blood vessels per 
field of view revealed a significant induction of angiogenesis in recurrent tumor after OV 
treatment when compared to untreated PBS control tumors (Figure 14b, P < 0.05).  The highly 
angiogenic nature of the residual disease may contribute toward reducing the efficacy of OV 
therapy.  This result has implications towards designing future clinical trials in conjunction with 
anti-angiogenic treatment. 
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Increased microvessel density of residual disease after OV treatment is the result of 
induction of CYR61, an angiogenic inducer, upon OV treatment.   
 
a:  PBS/OV treated animals were sacrificed when they showed signs of morbidity (Day 14 for 
PBS-treated,  Day 21 for OV-treated).  5 minutes prior to euthanization, the rats were tail vein 
injected with dextran conjugated to FITC (>60kDa) to stain perfused blood vessels in the tumor 
region.  A significant increase in microvessel density of residual disease after OV treatment is 
clearly visible when compared to the PBS treated tumor. 
 
b:  Microvessel density was quantified by counting the number of vessels per view field.  The 
angiogenic activity induced by CYR61 expression in the residual tumor is evident when 
compared to the untreated tumor sample (P<0.05).  The induction of neovascularization by 
CYR61 protein may lead to an aggressive recurrence of the residual tumor post OV therapy.    
a. b. 
Figure 14: Induction of CYR61, an Angiogenic Factor, upon OV 
Treatment Leads to Increased Microvessel Density of the Residual 
Disease. 
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Discussions and Conclusions 
OV-mediated tumor destruction is an exciting experimental therapy that is currently 
being tested in clinical trials.  These trials have revealed the incredible safety of OV treatment, 
wherein none to minimal signs of toxicity could be attributed directly to the virus 3,57.  
Nevertheless, the high expectations of this therapeutic modality remain unmet.  Changes in the 
tumor microenvironment induced by OV therapy can significantly impact the treatment’s 
effectiveness by altering the growth and spread of solid tumors 58,59.  Given the complicated 
interactions between cancerous cells and their microenvironment, we hypothesized that OV 
induced changes in the tumor environment would dictate the efficacy of this therapeutic 
modality.   
Here, we describe for the first time the induction of CYR61 upon OV infection of glioma 
cells.  CYR61 mRNA induction has been validated in multiple human glioma cell lines, as well 
as in patient derived tumor cells.  Furthermore, mRNA induction was observed upon infection 
with three different HSV-1-derived OVs.  Our study also confirms the induction of CYR61 
protein expression following OV treatment both in vitro and in vivo.  The consistent induction of 
CYR61 mRNA and protein expression upon OV infection indicates that this secreted protein can 
serve as a biomarker for OV activity; an elevation in CYR61 levels will accurately reflect 
ongoing viral infection, replication, and propagation.   
In addition, future studies investigating the mechanism of CYR61 induction could lead to 
the generation of imaging vectors that drive the expression of marker proteins under the 
governance of this OV inducible promoter.  These vectors can then be used to reflect OV 
activity, thereby allowing viral activity to be monitored in a non-invasive manner.  These studies 
would allow individual patient responses observed in clinical trials to be correlated to OV 
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activity in each patient by monitoring and evaluating changes in CYR61 levels in the patient’s 
tumor following OV treatment.  In addition, these studies may further clarify the interplay 
between the host’s innate viral clearing and adaptive anti-tumor immune responses and their 
effects upon OV therapy’s efficacy. 
Ongoing studies in the laboratory are exploring the effect of CYR61 on subsequent 
rounds of viral infection/replication and/or propagation in tumor tissue.  The effect of CYR61 on 
viral therapy is as yet unclear; the protein may function either to stimulate or inhibit subsequent 
viral treatments. Thus, future studies in the laboratory will be aimed at investigating the potential 
of using CYR61 levels in tumors as prognostic markers to predict patients who would benefit 
from OV therapy. 
Given the magnitude of tumor vasculature’s effect upon the tumor microenvironment, it 
is also probable that changes in tumor vasculature will greatly affect the outcome of OV therapy 
60.  Our studies show the effect of CYR61 protein in changing the biology of the residual disease 
by increasing angiogenesis after OV therapy.  These results reveal the importance of treating the 
tumor microenvironment alongside the cancerous cell to yield synergistic enhancement of 
therapy.   
 This study lays down a rationale for the treatment of tumors with OV in conjunction with 
anti-angiogenic agents to target both cancerous cells and tumor microenvironment.  Future 
studies will identify the feasibility of using CYR61 as a potential biomarker for OV activity in 
vivo. 
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